A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT07218341)
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (1 items) and avoid the listed exclusions (1 items).
Location: Mitchell Cancer Institute — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- Mitchell Cancer Institute — Mobile, Alabama
- Arizona Oncology Associates, P.C. - HOPE — Tucson, Arizona
- Cancer Specialists, LLC — Jacksonville, Florida
- Minnesota Oncology Hematology, P.A. — Coon Rapids, Minnesota
- Cayuga Cancer Center — Ithaca, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York — New York, New York
- Oncology Hematology Care Inc — Cincinnati, Ohio
- Texas Oncology - Paris — Fort Worth, Texas
- US Oncology - Texas Oncology — Kyle, Texas
- The Alfred Hospital — Melbourne,
- LKH - Universitätsklinikum der PMU Salzburg — Salzburg,
- AZ Delta — Roeselare,
- Princess Margaret Cancer Centre - University Health Network — Toronto,
- Xuanwu Hospital Capital Medical University — Beijing,
- Hunan Cancer Hospital — Changsha,
- Sun Yat-sen University Cancer Center — Guangdong,
- Nanfang Hospital of Southern Medical University — Guangzhou,
- Gansu Provincial Cancer Hospital — Lanzhou,
- The First Affiliated Hospital of Nanchang University — Nanchang,
- Fudan University Shanghai Cancer Center — Shanghai,
- Taizhou Hospital of Zhejiang Province — Taizhou,
- Hematology Hospital of the Chinese Academy of Medical Sciences — Tianjin,
- Tianjin Medical University Cancer Institute & Hospital — Tianjin,
- Affiliated Cancer Hospital of Xinjiang Medical University — Ürümqi,
- The Affiliated Hospital of Xuzhou Medical College — Xuzhou,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Lymphocytic Leukemia
- Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: — Vancouver, British Columbia
- Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects — Rochester, Minnesota
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia — Houston, Texas
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL — Los Angeles, California
- Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia — Rochester, Minnesota
Explore by condition: All Chronic Lymphocytic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.